Caris Life Sciences, Inc. operates at the intersection of biotechnology and artificial intelligence, offering advanced molecular profiling services for cancer patients. The company's core platform, Caris Molecular Intelligence, performs multi-omic profiling of solid tumors and hematologic malignancies to identify specific molecular alterations and biomarkers. In addition to tissue-based testing, Caris provides liquid biopsy solutions, such as Caris Assure, for disease monitoring and treatment selection. Beyond clinical diagnostics, the company leverages its massive proprietary clinico-genomic database through the Caris CODEai platform to generate actionable insights for biopharmaceutical research, clinical trial matching, and novel target discovery. Caris serves a global network of oncologists, pathologists, and researchers, driving advancements in personalized cancer care and therapeutic development.
